Multicomponent Pharmaceutical Solids
Multicomponent pharmaceutical materials are solids in which at least one component is an active pharmaceutical ingredient (API). This kind of pharmaceutical solid has attracted interest in the past decade as a promising alternative to the laborious and expensive process of traditional pipeline drug...
Saved in:
Other Authors: | , |
---|---|
Format: | Electronic Book Chapter |
Language: | English |
Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
Subjects: | |
Online Access: | DOAB: download the publication DOAB: description of the publication |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000naaaa2200000uu 4500 | ||
---|---|---|---|
001 | doab_20_500_12854_100063 | ||
005 | 20230511 | ||
003 | oapen | ||
006 | m o d | ||
007 | cr|mn|---annan | ||
008 | 20230511s2023 xx |||||o ||| 0|eng d | ||
020 | |a books978-3-0365-7217-8 | ||
020 | |a 9783036572161 | ||
020 | |a 9783036572178 | ||
040 | |a oapen |c oapen | ||
024 | 7 | |a 10.3390/books978-3-0365-7217-8 |c doi | |
041 | 0 | |a eng | |
042 | |a dc | ||
072 | 7 | |a GP |2 bicssc | |
072 | 7 | |a PH |2 bicssc | |
100 | 1 | |a Choquesillo-Lazarte, Duane |4 edt | |
700 | 1 | |a Dominguez-Martin, Alicia |4 edt | |
700 | 1 | |a Choquesillo-Lazarte, Duane |4 oth | |
700 | 1 | |a Dominguez-Martin, Alicia |4 oth | |
245 | 1 | 0 | |a Multicomponent Pharmaceutical Solids |
260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
300 | |a 1 electronic resource (178 p.) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
520 | |a Multicomponent pharmaceutical materials are solids in which at least one component is an active pharmaceutical ingredient (API). This kind of pharmaceutical solid has attracted interest in the past decade as a promising alternative to the laborious and expensive process of traditional pipeline drug development. The application of crystal engineering techniques into the design of pharmaceutical salts, co-crystals, and other multicomponent materials, in addition to the achievement of more environmentally friendly synthetic approaches, has succeeded in modulating the physicochemical, mechanical, and pharmacokinetic properties of drugs, thereby working toward the enhancement of their clinical performance. This Special Issue welcomed original research articles and reviews devoted to all aspects related to the field of multicomponent pharmaceutical solids. Our interests include the fundamentals of applied research, using theoretical and experimental approaches, the development of synthetic methods, the screening of multicomponent materials, structure-activity rationale, the salt-co-crystal continuum identification, the enhancement in physicochemical/mechanical/pharmacokinetic performance, as well as the functionality and applications of multicomponent pharmaceuticals solids. | ||
540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
546 | |a English | ||
650 | 7 | |a Research & information: general |2 bicssc | |
650 | 7 | |a Physics |2 bicssc | |
653 | |a solvate | ||
653 | |a polymorph | ||
653 | |a bilastine | ||
653 | |a crystal structure determination | ||
653 | |a single crystal X-ray diffraction | ||
653 | |a structure determination from powder diffraction | ||
653 | |a aripiprazole | ||
653 | |a multicomponent crystal | ||
653 | |a crystal structure | ||
653 | |a solubility | ||
653 | |a drug-drug cocrystal | ||
653 | |a furosemide | ||
653 | |a ethenzamide | ||
653 | |a piroxicam | ||
653 | |a mechanochemical synthesis | ||
653 | |a amorphous drug | ||
653 | |a characterization methods | ||
653 | |a crystallization | ||
653 | |a physical stability | ||
653 | |a molecular mobility | ||
653 | |a aminoglutethimide | ||
653 | |a eutectic mixture | ||
653 | |a melt phase diagram | ||
653 | |a nucleobases | ||
653 | |a multicomponent solids | ||
653 | |a crystal engineering | ||
653 | |a DFT | ||
653 | |a H-bonding | ||
653 | |a pyridinecarboxamides | ||
653 | |a cocrystals | ||
653 | |a mandelic acid | ||
653 | |a X-ray structure | ||
653 | |a DFT calculations | ||
653 | |a xanthines | ||
653 | |a theophylline | ||
653 | |a squaric acid | ||
653 | |a controlled release | ||
653 | |a dissolution | ||
653 | |a lidocaine | ||
653 | |a mechanochemistry | ||
653 | |a multicomponent materials | ||
653 | |a API | ||
653 | |a pharmaceutical solids | ||
653 | |a diclofenac | ||
653 | |a pharmaceutical solid forms | ||
653 | |a n/a | ||
856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/7156 |7 0 |z DOAB: download the publication |
856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/100063 |7 0 |z DOAB: description of the publication |